As demonstrated in many studies, the costs associated with CPAP therapy are no longer seen as an obstacle. Several national healthcare systems (e.g. US, Canada, UK) recently assessed the efficacy of the therapy and confirmed its benefits:
An economic analysis conducted in the US compared CPAP with other types of available therapies for adults with moderate or severe symptomatic OSAHS (obstructive sleep apnoea-hypopnoea syndrome) and concluded that CPAP1 is a cost-effective treatment.
A similar study in Canada considered costs and impact on quality of life, as well as the risk of motor vehicle crashes among individuals with OSAHS. The study concluded that CPAP therapy provided a highly efficient use of healthcare resources2.
CPAP was found to be clinically more effective than no treatment and, from the perspective of the UK’s National Health Service, a cost-effective strategy after a minimum of two years of treatment3.
1 Weatherly HL, Griffin SC, McDaid C, Durée KH, Davies RJ, Stradling JR, Westwood ME, Sculpher MJ, Centre for Health Economics, University of York, York, UK. firstname.lastname@example.org. An economic analysis of continuous positive airway pressure for the treatment of obstructive sleep apnoea-hypopnoea syndrome. Int J Technol Assess Health Care. 2009 Jan;25(1):26-34.
2 Tan MC, Ayas NT, Mulgrew A, Cortes L, FitzGerald JM, Fleetham JA, Schulzer M, Ryan CF, Ghaeli R, Cooper P, Marra CA, Vancouver Coastal Health Research Institute, Vancouver, Canada. Cost-effectiveness of continuous positive airway pressure therapy in patients with obstructive sleep apnoea-hypopnoea in British Columbia. Can Respir J. 2008 Apr;15(3):159-65.
3 Guest JF, Helter MT, Morga A, Stradling JR. Catalyst Health Economics Consultants, 34b High Street, Northwood, Middlesex HA6 1BN, UK. email@example.com. Cost-effectiveness of using continuous positive airway pressure in the treatment of severe obstructive sleep apnoea/hypopnoea syndrome in the UK. Thorax. 2008 Oct;63(10):860-5. Epub 2008 Apr 11.